GIVEAWAY: Omnipod Pullover
A few years ago I spoke at an event and came home with this beautiful and incredibly comfortable pullover for Arden - but it didn’t fit her and so it went to live in her closet. I present it here today, never worn, soft as a cloud and ready for the winner of this Giveaway.
item: The giveaway is for one pullover, Ladies Extra Small. It is the shirt you see in the photos below. The item has no cash value. Complete giveaway rules are here.
shipping: Anyone can enter but if you are outside of the United States I may ask you to help with shipping, sound fair?
Here’s how you can accumulate entry points (the more points you have, the better your chances are of being drawn at random).
Leave a review for the Juicebox Podcast on Apple Podcasts (iTunes) you’ll receive, 5 points.
Leave a review on the Bold With Insulin Facebook page, 3 points.
Subscribe to the Juicebox Podcast in your favorite podcast app, 1 point.
Email, text or tell someone about the Juicebox Podcast and then help them to subscribe, 1 point.
All entries are made through the Rafflecopter app below. Please note that review entries require you to leave your username (used for the review) so I can verify your entry.
Apple Reviews have three parts. Click to enlarge.
Try a free, no obligation Omnipod demo today.
Dexcom Real-Time Status Page
Dexcom launches an always-on, real-time status page!
There is now a webpage where customers, healthcare providers and loved ones can check the status of all Dexcom systems 24 hours a day, 7 days a week. This page is the first of several updates that Dexcom is putting in place. Spoilers: Look for the launch of an in-app messaging feature that is planned for the near future.
What are you waiting for, go check it out!
click> status.dexcom.com
Bump and Nudge
Mini-Post: Bump and Nudge
Arden woke up for school at 6:30 am with a BG of 71 but wasn’t planning on eating before she left for school. About 45 minutes later her BG began to drift lower and she still wasn’t hungry. The drift had momentum because her basal rate increases at 7 am for her school day insulin needs. So we bumped the number with chewable vitamins - just 5 carbs but they worked perfectly. Her BG went to 101 and then drifted back to 91. She did not eat until noon and never experienced a low.
To learn more about bumping and nudging check out episode #225 of the Juicebox Podcast (look down). If you like it consider heading back to episode 210 and listening to the entire Diabetes Pro Tip Series.
FDA approves Fiasp® for treatment of children with diabetes
PLAINSBORO, N.J., Jan. 6, 2020 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp® (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.1 Fiasp® is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp® is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
Diabetes is one of the most common chronic conditions diagnosed in childhood, with nearly 18,000 new cases of type 1 diabetes each year.2,3 Managing diabetes can be challenging for parents and caregivers given it is hard to know exactly how much or how quickly their children will eat, making mealtime insulin dosing difficult.3,4,5 Conventional rapid-acting insulins must be administered ahead of meals, which requires some guesswork to dose properly, and children living with diabetes may not achieve adequate blood sugar control.3,4,5,6
“As a parent of a son living with type 1 diabetes, I know first-hand how tough it can be to address the inevitable blood sugar spikes around mealtimes,” said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. “Children can be unpredictable and having the option of a fast-acting insulin that doesn’t require pre-meal dosing like Fiasp® is a welcome development for the diabetes community.”
The approval is based on the FDA's review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp® in children. 7
For information on cost and savings offers, including co-pay and patient assistance programs, visit myfiaspcost.com.
Sanofi to Exit Diabetes Research
“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history. As tough a choice as that is, we’re making that choice.”
The maker of the world’s top-selling insulin has given up on finding new diabetes drugs. which makes Lantus, said Monday it would stop investing in diabetes research after years of frustrated attempts to bring a fresh blockbuster to the market.
The decision is part of a broader strategic overhaul by new Chief Executive Paul Hudson, who hopes to reinvigorate growth at the French health-care giant by focusing on fewer, more specialized disease areas such as cancer—mirroring a move being made across the drug industry.
Read the entire article here